New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
16:23 EDTPDIIPDI, Inc. sees FY12 revenue $127M-$130M, consensus $137.53M
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
06:33 EDTPDIIPDI, Inc. announces continued Medicare coverage for PancraGEN
PDI, Inc. subsidiary, Interpace Diagnostics, announced that Novitas Solutions, the Medicare Administrative Contractor, or MAC, for Interpace Diagnostics, has updated its Local Coverage Determination, or LCD, for PancraGEN. The PancraGEN test utilizes the PathFinderTG platform. The original coverage issued on November 5, 2010 provided "Coverage with Appropriateness Development," which required the company to routinely present updated data to further validate the test's effectiveness. The new policy no longer includes this condition for coverage and is effective December 31 and ensures continued coverage of PancraGEN for Medicare eligible patients. This updated coverage was achieved due to the increasing body of evidence including the publication of the results of the pivotal PancraGEN 492 patient multicenter National Pancreatic Cyst registry clinical validation study in the February 2015 issue of Endoscopy.i The study concluded that PancraGEN is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients' likelihood of developing pancreatic cancer.
November 12, 2015
16:11 EDTPDIIPDI, Inc. backs FY15 revenue view $136M-$140M, one estimate $140.17M
Sees FY15 company-wide gross margin 18%, up from 15.5% in 2014. 2015 adjusted operating loss is now expected to be $14M-$16M vs. the previous forecast of $16M-$18M.
16:09 EDTPDIIPDI, Inc. reports Q3 EPS (31c), one estimate (40c)
Reports Q3 revenue $36.6M, one estimate $32.35M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use